PreciseOnco The next leap in cancer care: combining multi-modality and spectral imaging, advanced therapies, robotics and AI to enable standardized, precise interventional oncology treatments for cancer patients
- Coordinator
- Philips Medical Systems Nederland BV, Netherlands
- Runs
- 1 January 2026 to 31 December 2030
- Status
- Running
- EU funding
- €14.9m
- Total cost
- €23.9m
- Partners
- 15 organisations in 6 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101252582
What the project is doing
In the project's own words, from its summary on CORDIS.
Every year, millions of people around the world face a cancer diagnosis, and for many of them, precise and minimally invasive treatments offer the best hope for recovery. However, delivering these treatments accurately—especially deep inside the body—remains a major challenge. This project, PreciseOnco, aims to revolutionize how doctors plan, guide, and evaluate cancer therapies using the latest breakthroughs in medical imaging and robotics.
At the heart of our work is a new generation of imaging technology, called spectral imaging, which can distinguish between different types of tissue and treatment materials with much greater clarity than current scans. This allows doctors to see tumors more clearly, guide needles with improved accuracy, and monitor treatments in real time. We will also introduce motion correction tools that account for patient breathing and other natural movements during procedures which make the scans sharper, faster, and more reliable.
In addition, we will integrate robotic assistance into treatment workflows to help doctors place needles with sub-millimeter precision. This will reduce variability between operators, shorten procedure times, and make complex treatments more widely accessible, even in smaller hospitals. Our advanced software and AI tools will make it easier to plan, deliver, and confirm treatments without extra scans or delays. We will test these innovations in real-world clinical studies, including treatment of liver and kidney tumors, where today’s tools often fall short.
Ultimately, PreciseOnco aims to make cancer interventions safer, more targeted, and more successful which will offer patients better outcomes with less burden.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Philips Medical Systems Nederland BV | Best | Netherlands | Coordinator |
| Cardiovascular and Interventional Radiological Society of Europe | Wien | Austria | Participant |
| Eibir Gemeinnutzige GmbH Zur Forderung Der Erforschung Der Biomedizinischen Bildgebung | Wien | Austria | Participant |
| Philips Belgium Commercial | Bruxelles | Belgium | Participant |
| Klinikum Der Universitaet Zu Koeln | Koeln | Germany | Participant |
| Philips GmbH | Hamburg | Germany | Participant |
| Assistance Publique Hopitaux De Paris | Paris | France | Participant |
| Hospices Civils De Lyon | Lyon | France | Participant |
| Philips France | Suresnes | France | Participant |
| Quantum Surgical | Montpellier | France | Participant |
| Igea SpA | Carpi Mo | Italy | Participant |
| Academisch Ziekenhuis Leiden | Leiden | Netherlands | Participant |
| Philips Electronics Nederland BV | Eindhoven | Netherlands | Participant |
| Philips Electronics Nederland BV | Eindhoven | Netherlands | Third party |
| Universitair Medisch Centrum Utrecht | Utrecht | Netherlands | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI